ChemLex, a next-generation AI-for-science company, today announced the establishment of its global headquarters and self-driving laboratory in Singapore, alongside the close of a USD 45 million funding round led by Granite Asia. Founded in 2022, ChemLex develops AI technologies that radically accelerate chemical discovery for the pharmaceutical industry, significantly reducing time-to-market. In just three and […]

AI/ML health-tech startupRespiree has received approval from the Health Sciences Authority (HSA) for its 1Bio™AI-Acute toolbox as a Class B software-as-a-medical device (SaMD). The solution is designed to support healthcare professionals in identifying acute inpatient deterioration using AI-enabled machine learning models. Compared to the current standard of care, 1Bio™AI-Acute delivers significantly higher precision in acute

(NASDAQ:HCM),(LSE – AIM:HCM),(HKSE:0013), HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2026 will continue to include ELUNATE(R),

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China GlobeNewswire December 08, 2025 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the “Class Period”), of the important December 29, 2025 lead plaintiff deadline. So what: If you purchased Avantor common stock during the Class

https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CarMax, Inc. (NYSE: KMX) between June 20, 2025 and November 5, 2025, both dates inclusive (the “Class Period”), of the important January 2, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If

(NasdaqGM:GPCR), SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule GLP-1 receptor

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 GlobeNewswire December 07, 2025 SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus

(NASDAQ:IMMX), LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants GlobeNewswire December 07, 2025 LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering